Business Wire

TX-SNOW-SOFTWARE

17.11.2022 15:01:53 CET | Business Wire | Press release

Share
IT Leaders May Underestimate the Risk of Shadow SaaS, Finds New Snow Software Survey

Snow Software, the global leader in technology intelligence, today unveiled new data highlighting the challenges facing IT leaders due to expanded software as a service (SaaS) usage. While a huge majority of IT leaders (96%) indicated they were ‘confident or very confident’ in their organization’s SaaS security measures, the top challenge for leaders managing SaaS was ‘employees adding new SaaS applications without notifying IT,’ suggesting that leaders may underestimate the importance of visibility in security.

According to IDC, SaaS is the top source for cloud spend in 2022, accounting for $177.8 billion of the market. In the new Snow survey examining the state of SaaS management, which surveyed 1,000 IT leaders from large organizations of 500+ employees in the United States and United Kingdom, 44% said ‘employees adding new SaaS applications without notifying IT’ is their top challenge to managing SaaS applications at their organization, closely followed by managing SaaS security (42%). When asked why these issues were so challenging, IT leaders indicated the impact to other IT programs (47%), organizational dynamics (38%), lack of time and resources (37%) and lack of visibility (36%).

“Post-pandemic IT teams are seeing a large increase in SaaS applications procured without the knowledge of IT,” said Becky Trevino, Executive Vice President of Products at Snow. “Amid increasing cybersecurity risks and mounting pressure to cut costs, IT leaders realize they need to better govern unknown and unsanctioned SaaS usage. CIOs are ultimately responsible for the security and management of SaaS applications regardless of where they are procured, and to do this effectively IT needs complete visibility into what it is they need to secure.”

Views on budget and security ownership depends on your leadership level

Cybersecurity is a major focus for IT decision-makers right now, particularly as business leaders navigate market uncertainty and plan 2023 budgets in anticipation of a recession. However, ownership is not clear among IT leaders, which can put organizations at risk for elevated costs and gaps in security.

  • IT leaders ranked ‘managing the security of SaaS applications’ as the #1 most important issue to managing SaaS applications at their organization, followed by ‘identifying usage of all SaaS applications within our organization.’
  • Ninety-six percent of those surveyed reported feeling ‘confident’ or ‘very confident’ in their organization’s SaaS security measures.
  • According to the survey, SaaS purchasing power and IT/security responsibility rests firmly within two groups: CIOs/IT leadership and IT asset management (ITAM) or software asset management (SAM) teams.
  • Senior leaders (41% of vice presidents, 45% of sr. vice presidents and 52% of C-level executives) look to the CIO and/or IT leadership to take responsibility for SaaS purchasing and security issues over other departments and roles, while more mid-level management (50% of managers and 44% of directors) put the onus of SaaS management and security on peers within ITAM/SAM.
  • Forty-eight percent of IT leaders surveyed said that if budget, resources and time were not a factor, they’d like to pivot all SaaS application spending to IT to address SaaS sprawl.

Economic uncertainty is elevating cost concerns among IT leaders – though it’s not the top priority

Market conditions are driving increased scrutiny across all areas of cost in most organizations and optimizing spend while eliminating waste is an ongoing priority for IT teams. However, of those surveyed, IT leaders are currently more focused on cybersecurity of SaaS applications than costs.

  • Despite continued uncertainty across the global markets, reining in the total cost of SaaS applications was ranked 5th on respondents’ priorities.
  • If global uncertainty persists, more than three quarters of all respondents (77%) believe IT spend will decrease by as much as 50% to 75%.
  • If IT spending decreases, IT leaders believe that the two core areas impacted will be IT staffing (20%) and strategic IT initiatives or programs (19%).

For more information about Snow’s latest survey, please visit: https://www.snowsoftware.com/blog/survey-anxiety-over-saas-security-plagues-it-leaders/

About Snow Software

Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005232/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye